Major depressive disorder market to reach $7.87bn in 8MM by 2029

21 October 2021

The prevalence of major depressive disorder (MDD) – a highly debilitating condition often known as clinical depression - is expected to increase due to COVID-19-related stress.

While the effect of the pandemic on the diagnosed MDD patient population is as of yet unquantified, the stress-inducing factors of COVID-19 such as a long duration of quarantine, fears of infection, inadequate information from authorities, stigma and financial loss will lead to a higher prevalence of depressive symptoms worldwide.

Data and analytics company GlobalData notes that the MDD market in the eight leading markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan and China is expected to reach $7.87 billion by 2029, up from $3.39 billion in 2019, with eight new pipeline products set to address the unmet needs of a growing patient population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK